[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100345245":3},{"organization":4,"outcomesModule":7,"designInfo":7,"detailedDescription":8,"studyPopulation":7,"armGroups":7,"interventions":9,"overallOfficials":7,"centralContacts":17,"locations":7,"responsibleParty":23,"collaborators":7,"id":25,"slug":7,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":7,"acronym":7,"eligibilityCriteria":29,"healthyVolunteers":26,"sex":30,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":31,"phases":7,"briefSummary":32,"conditions":33,"keywords":36,"overallStatus":41,"whyStopped":7,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":46,"locationsCount":7},{"fullName":5,"class":6},"Kyowa Kirin Co., Ltd.","INDUSTRY",null,"Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies. For full details, please visit the links provided below.",[10],{"type":11,"name":12,"description":7,"armGroupLabels":7,"otherNames":13},"BIOLOGICAL","Burosumab",[14,15,16],"UX023","Crysvita®","KRN23",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Development Division Project Management Department","CONTACT","609-919-1100","kkd.clintrial.82@kyowakirin.com",{"type":24,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100345245",false,"NCT03775187","Expanded Access to Burosumab","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","ALL","EXPANDED_ACCESS","Individual patient expanded access requests may be considered for patients who have no other treatment options",[34,35],"X-linked Hypophosphatemia","Tumor-Induced Osteomalacia",[37,38,39,40],"Expanded Access","Compassionate Use","XLH","TIO","AVAILABLE","2025-02-28",{"date":44,"type":45},"2025-03-05","ACTUAL",{"name":5,"class":6}]